D
David Planchard
Researcher at Institut Gustave Roussy
Publications - 430
Citations - 28831
David Planchard is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 55, co-authored 352 publications receiving 19769 citations. Previous affiliations of David Planchard include Université Paris-Saclay & Princess Margaret Cancer Centre.
Papers
More filters
Journal ArticleDOI
Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
S.J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,A. Chiappori,K.H. Lee,M. de Wit,Byoung Chul Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Yun-Hyeon Kim,Chris Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,J. De Castro Carpeno,Corinne Faivre-Finn,Martin Reck,Johan Vansteenkiste,David R. Spigel,C. Wadsworth,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu +31 more
Journal ArticleDOI
Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
Cesare Gridelli,Paul Baas,Fabrice Barlesi,Fortunato Ciardiello,Lucio Crinò,Enriqueta Felip,Shirish M. Gadgeel,Vassiliki A. Papadimitrakopoulou,Luis Paz-Ares,David Planchard,Maurice Pérol,Nasser H. Hanna,Assunta Sgambato,Francesca Casaluce,Filippo de Marinis +14 more
TL;DR: The second‐line algorithm treatment of NSCLC becomes very intricate and the selection of proper patients with one of the new available therapeutic options is of paramount importance to personalize and optimize the treatment.
Journal ArticleDOI
OA22.02 Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial
Federica Grosso,Nicola Steele,Silvia Novello,Anna K. Nowak,Sanjay Popat,Laurent Greillier,Thomas John,Natasha B. Leighl,Martin Reck,Paul J. Taylor,Nick Pavlakis,Jens Benn Sørensen,David Planchard,Giovanni Luca Ceresoli,Brett G.M. Hughes,Julien Mazieres,Mark A. Socinski,Martha Mueller,Ute von Wangenheim,Arsene Bienvenu Loembe,N. Morsli,José Barrueco,Giorgio V. Scagliotti +22 more
Three-year overall survival update from the PACIFIC trial.: 2018 ASCO Annual Meeting Abstracts
Jhanelle E. Gray,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,Alberto Chiappori,Ki Hyeong Lee,Byoung Chul Cho,David Planchard,Luis Paz-Ares,Corinne Faivre-Finn,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu,Scott J. Antonia +19 more
TL;DR: The PACIFIC study as mentioned in this paper showed that durvalumab showed significant improvements versus placebo in the primary endpoints of progression-free survival (HR 0.52; 95% CI, 0.42-0.65).
Journal ArticleDOI
Are we reproducible in measurement of NET liver metastasis
Salma Moalla,Julia Arfi Rouche,Stéphanie Foulon,Caroline Caramella,Nils Ternès,David Planchard,Diane Goéré,Michel Ducreux,Jean-Yves Scoazec,Frederic Deschamps,Clarisse Dromain,Eric Baudin +11 more
TL;DR: The MRI sequence offering the best intra and inter-observer reproducibility is the T2W-sequence, and non-enhanced MRI should be preferred to triphasic-CT for follow-up, assessment of treatment and trials.